CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-06 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −4,170 | $13.43 | $56K | 147,712 |
| 2026-03-02 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −4,170 | $15.01 | $63K | 151,882 |
| 2026-03-02 | Watkins Tim CMO & Head of Development | Option exercise 10b5-1 | +3,611 | $4.50 | $16K | 3,611 |
| 2026-03-02 | Watkins Tim CMO & Head of Development | Sale 10b5-1 | −3,611 | $15.02 | $54K | 0 |
| 2026-03-02 | Watkins Tim CMO & Head of Development | Option exercise · Stock Option (right to buy) 10b5-1 | −3,611 | 249,167 | ||
| 2026-02-25 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +2,700 | $1.26 | $3K | 17,654 |
| 2026-02-25 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −2,700 | $16.02 | $43K | 14,954 |
| 2026-02-25 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −2,700 | 120,917 | ||
| 2026-02-25 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +3,824 | $1.01 | $4K | 159,876 |
| 2026-02-25 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −3,824 | $16.01 | $61K | 156,052 |
| 2026-02-25 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,824 | 67,306 | ||
| 2026-02-24 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +4,400 | $1.26 | $6K | 19,354 |
| 2026-02-24 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −4,400 | $16.02 | $70K | 14,954 |
| 2026-02-24 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −4,400 | 123,617 | ||
| 2026-02-24 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +4,300 | $1.01 | $4K | 160,352 |
| 2026-02-24 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −4,300 | $16.03 | $69K | 156,052 |
| 2026-02-24 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −4,300 | 71,130 | ||
| 2026-02-19 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +100 | $1.01 | $101 | 156,152 |
| 2026-02-19 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −100 | $16.00 | $2K | 156,052 |
| 2026-02-19 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −100 | 75,430 |
Page 3 of 7 · 139 trades